AU2021315234A1 - Therapeutic agent for breast cancer - Google Patents

Therapeutic agent for breast cancer Download PDF

Info

Publication number
AU2021315234A1
AU2021315234A1 AU2021315234A AU2021315234A AU2021315234A1 AU 2021315234 A1 AU2021315234 A1 AU 2021315234A1 AU 2021315234 A AU2021315234 A AU 2021315234A AU 2021315234 A AU2021315234 A AU 2021315234A AU 2021315234 A1 AU2021315234 A1 AU 2021315234A1
Authority
AU
Australia
Prior art keywords
breast cancer
therapeutic agent
estrogen receptor
acceptable salt
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021315234A
Other languages
English (en)
Inventor
Sayo FUKUSHIMA
Satoshi Kawano
Saori MIYANO
Kyoko NISHIBATA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2021315234A1 publication Critical patent/AU2021315234A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2021315234A 2020-07-31 2021-07-29 Therapeutic agent for breast cancer Pending AU2021315234A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020130935 2020-07-31
JP2020-130935 2020-07-31
JP2020163258 2020-09-29
JP2020-163258 2020-09-29
PCT/JP2021/028008 WO2022025150A1 (ja) 2020-07-31 2021-07-29 乳がん治療剤

Publications (1)

Publication Number Publication Date
AU2021315234A1 true AU2021315234A1 (en) 2023-01-19

Family

ID=80035757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021315234A Pending AU2021315234A1 (en) 2020-07-31 2021-07-29 Therapeutic agent for breast cancer

Country Status (11)

Country Link
US (1) US20230172924A1 (https=)
EP (1) EP4151212A4 (https=)
JP (1) JP7792336B2 (https=)
KR (1) KR20230047056A (https=)
CN (1) CN115996722A (https=)
AU (1) AU2021315234A1 (https=)
BR (1) BR112022027069A2 (https=)
CA (1) CA3185174A1 (https=)
MX (1) MX2023000060A (https=)
TW (1) TW202220652A (https=)
WO (1) WO2022025150A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809312A1 (en) * 2012-01-31 2014-12-10 Novartis AG Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
CN108367000A (zh) 2015-12-17 2018-08-03 卫材R&D管理有限公司 用于乳腺癌的治疗剂
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
JP2018022750A (ja) 2016-08-02 2018-02-08 太陽誘電株式会社 積層セラミックコンデンサ
US11219619B2 (en) * 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
EP4122465A4 (en) * 2020-04-17 2024-03-20 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT AGAINST BREAST CANCER

Also Published As

Publication number Publication date
TW202220652A (zh) 2022-06-01
JP7792336B2 (ja) 2025-12-25
US20230172924A1 (en) 2023-06-08
BR112022027069A2 (pt) 2023-02-07
JPWO2022025150A1 (https=) 2022-02-03
MX2023000060A (es) 2023-02-01
CA3185174A1 (en) 2022-02-03
EP4151212A1 (en) 2023-03-22
KR20230047056A (ko) 2023-04-06
EP4151212A4 (en) 2024-04-10
WO2022025150A1 (ja) 2022-02-03
CN115996722A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
US20250177406A1 (en) Pharmaceutical composition for treating tumors
EP3581183B1 (en) Tumor-treating pharmaceutical composition
TWI906299B (zh) 單一療法及組合療法
CN106572990A (zh) 含有雌激素受体调节剂的治疗性组合产品
IL293208A (en) Combination therapy involving diaryl macrocyclic compounds
TW202132299A (zh) 組合
US20230119759A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
US20230149381A1 (en) Breast cancer therapeutic agent
EP1845990B1 (en) Treatment of metastasized tumors
KR20150023880A (ko) 안드로겐 수용체 길항제로서의 ｎ-[4-(퀴놀린-4-일옥시)사이클로헥실(메틸)](헤테로)아릴카복사미드, 그의 제조, 및 의약품으로서의 그의 용도
AU2021315234A1 (en) Therapeutic agent for breast cancer
EP3012248B1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
WO2012082992A1 (en) Compositions and methods for cancer treatment
ES2991018T3 (es) (N-(2-((2-bencilfenil)amino)-2-oxoetil)-L-naftamida) como agente terapéutico anticanceroso
RU2847580C1 (ru) Терапевтическое средство против рака молочной железы
TW202135814A (zh) 組合
WO2025167971A1 (zh) Pkmyt1抑制剂的药物组合及其用途
JP2023046235A (ja) 医薬組成物及びｓｔａｔ３のリン酸化阻害剤
CN120712263A (zh) 瞬时受体电位香草素6抑制剂
CN104684896B (zh) 作为雄激素受体拮抗剂的n‑[4‑(喹啉‑4‑基氧基)环己基(甲基)](杂)芳基甲酰胺、其制法及其用作药品的用途
WO2009138779A1 (en) Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
BR112021015004A2 (pt) Derivados de 2 h-indazol como agentes terapêuticos para cânceres cerebrais e metastases cerebrais
HK1233492A1 (en) Therapeutic combinations with estrogen receptor modulators
HK1206346B (en) N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products